PFE heads into mid-August with an unusual confluence: short sellers are cutting positions at pace, directors are stepping in with near-seven-figure purchases, and the Street is grinding targets lower — all at the same time.
The most eye-catching move this week came from inside the boardroom. Two independent directors bought PFE in size on August 5, with Mortimer Buckley acquiring roughly $960k worth of shares at $25.52 and Ronald Blaylock adding just under $1 million at $25.46. Net insider activity for the 90-day window flipped positive at just over $2 million bought — a meaningful contrast to the routine executive sales from the Chief Accounting Officer that dominate the recent trade log. Directors buying near-term lows at this scale is rare for a mega-cap pharma name and suggests at least some board-level conviction that the stock had been oversold.
Short positioning reinforces that read. Short interest dropped 14% across the week to 2.6% of the free float — a low absolute level that leaves little meaningful squeeze pressure in the lending market. Borrow costs have eased sharply too, down a third over the past week to just 0.36%, a level consistent with no stress whatsoever in the borrow market. Availability is effectively unconstrained, with the lending pool showing far more shares available than are currently borrowed. Options positioning adds no drama: the put/call ratio of 0.84 is almost exactly in line with its 20-day average and sits comfortably in the middle of its 52-week range between 0.64 and 0.95. Taken together, the positioning picture is one of de-risking rather than active short pressure — bears are stepping back, not piling in.
The Street, however, is more cautious than the insiders. Target prices have moved in one direction for weeks. Guggenheim trimmed from $35 to $31 on August 7 while holding its Buy rating. JPMorgan, BofA, BMO and HSBC all cut targets through July, the latter pair downgrading or moving to neutral while doing so. The consensus mean target of $28.64 implies modest upside from the current $26.62 — but the direction of travel on that target is clearly downward. Bulls point to ~$60 billion in annual revenues, a portfolio anchored by Prevnar, Ibrance and Eliquis, and forward earnings growth that ranks in the 87th percentile of the universe — the forward EPS picture is recovering sharply off a depressed base. Bears counter with gross-to-net headwinds on premium medicines and the structural revenue gap left by the pandemic-era products. The valuation is undemanding, with a P/E of 9.1x and EV/EBITDA of 8.6x, and the dividend yield factors score at the 95th percentile — income-oriented holders have a clear reason to stay.
The stock recovered 4.8% on the week to $26.62 after a rough month that has seen it drift within a tight range. Closest peer BMY fell 3.5% on the week — making PFE's relative outperformance genuine rather than sector-driven. The next scheduled catalyst is the Q3 earnings print, currently flagged for November 3. The most recent Q2 result, reported August 4, produced a one-day gain of 3.1% and a five-day follow-through of 6.4% — suggesting the stock can react positively to earnings when execution holds up.
With shorts at multi-week lows and directors buying near the August intraday lows, the borrow and insider data are aligned in the same direction. The November earnings call will be where analysts test whether the forward EPS recovery story is translating into actual numbers — and whether those target cuts from July's reset have found a floor.
See the live data behind this article on ORTEX.
Open PFE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
